Clinical Trials Logo

Malignant Pancreatic Neoplasm clinical trials

View clinical trials related to Malignant Pancreatic Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05523154 Active, not recruiting - Clinical trials for Malignant Pancreatic Neoplasm

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

Start date: January 19, 2023
Phase: Early Phase 1
Study type: Interventional

This early phase I trial evaluates nanopore sequencing for its ability to detect bacteria in bile and prevent surgical site infections in patients undergoing surgery for benign or malignant pancreatic tumors. Surgical site infections are a significant source of poor outcomes in patients undergoing surgery for pancreatic tumors. In most patients who develop this kind of infection, the bacteria identified as causing the infection is also frequently found to be in the bile at time of surgery. Using nanopore sequencing to detect bacteria in the bile of patients undergoing surgery may allow doctors to prevent surgical site infections or treat them sooner or more effectively.

NCT ID: NCT03168737 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Start date: September 22, 2017
Phase: Phase 1
Study type: Interventional

This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors. Using 18F-fluoroazomycin arabinoside with PET-CT may help doctors plan better treatment for patients with solid tumors. 18F-fluoroazomycin arabinoside may help to show how much oxygen is present in a tumor during a PET-CT scan.